Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L34 pseudogene 16 (RPL34P16) is a processed pseudogene in the human genome. It shares sequence similarity with the functional gene encoding ribosomal protein L34 (RPL34), which is a structural constituent of the large 60S ribosomal subunit involved in protein synthesis. However, RPL34P16 does not produce a functional protein product and is not implicated in canonical biological functions, therapeutic targeting, or disease processes. Its main significance is as a genomic remnant arising from duplication or retrotransposition events during evolution. RPL34P16 is not a real therapeutic target but rather a processed pseudogene, thus not functionally relevant as an enzyme, receptor, transporter, or other drug target. If you are seeking information about protein-coding ribosomal protein L34, that is RPL34, not RPL34P16.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L34 pseudogene 16 (RPL34P16).